Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Stereotactic pallidotomy for Trtm of Parkinson's Disease, Efficacy & Adverse Effects at 6 Mo in 26 Pts
Neurol 50:434-438, Shannon,K.M.,et al, 1998
Assessment of Motor Function After Stereotactic Pallidotomy
Neurol 50:266-270, Ondo,W.G.,et al, 1998
Double-Blind Evaluation of Subthalamic Nucleus Deep Brain Stimulation in Advanced Parkinson's Disease
Neurol 51:850-855, Kumar,R.,et al, 1998
Treatment of Advanced Parkinson's Disease by Posterior GPi Pallidotomy:1-Year Results of a Pilot Study
Ann Neurol 40:355-366, 3411996., Baron,M.S.,et al, 1996
Does Ageing Aggravate Parkinsonisn Disability?
JNNP 54:780-782, Blin,J.,et al, 1991
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
The Laser Shoes
Neurol 90:e164-e171, Barthel, C.,et al, 2018
Long-Term Safety and Tolerability of ProSavin, a Lentiviral Vector-Based Gene Therapy for Parkinsons Disease: A Dose Escalation, Open-Label, Phase 1/2 Trial
Lancet 383:1138-1146,1107, Palfi, S.,et al, 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Extended-Release Pramipexole in Advanced Parkinson Disease
Neurol 77:767-774, Schapira, A.H.V.,et al, 2011
Cycling for Freezing of Gait
NEJM 362:e46, Snijders,A.H., &Bloem,B.R., 2010
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
Ropinirole 24-Hour Prolonged Release: Randomized, Controlled Study in Advanced Parkinson Disease
Neurol 68:1108-1115, Pahwa,R.,et al, 2007
Practice Parameter: Treatment of Parkinson Disease with Motor Fluctuations and Dyskinesia (An Evidence-Based Review)
Neurol 66:983-995, Pahwa,R.,et al, 2006
A Randomized Trial of Deep-Brain Stimulation for Parkinsons Disease
NEJM 355:896-908, Deuschl,G.,et al, 2006
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Arch Neurol 62:241-248, The PRESTO Study, 2005
Rasagiline as an Adjunct to Levodopa in Patients With Parkinsons Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily, Study)
Lancet 365:947-954, 914, Rascol,O., et al, 2005
Stalevo for Parkinson's Disease
The Medical Letter 46:39, , 2004
Subthalamic DBS Replaces Levodopa in Parkinson's Disease
Neurol 58:396-401, Vingerhoets,F.J.G.,et al, 2002
What Contributes to Quality of Life in Patients with Parkinson's Disease?
JNNP 69:308-312,289, Schrag,A. et al, 2000
Comparative Effects of Unilateral and Bilateral Subthalamic Nucleus Deep Brain Stimulation
Neurol 53:561-566, Kumar,R.,et al, 1999
Random, Placebo-Contr Study of Tolcapone in Pts with Fluctuating Parkinson Dis Trtd With Levodopa-Carbidopa
Arch Neurol 55:1089-1095, Adler,C.H.,et al, 1998
Bilateral High-Frequency Stimulation of the Internal Globus Pallidus in Advanced Parkinson's Disease
Ann Neurol 44:953-961, Volkmann,J.,et al, 1998
COMT Inhibition with Tolcapone Reduces the"Wearing Off"Phenomenon & Levodopa Requirements in Fluctuating Parkinsonisn Pts
JNNP 63:421-428, Baas,H.,et al, 1997
Tolcapone Improves Motor Function in Parkinsonian Pts with the"Wearing Off"Phenomenon
Neurol 49:1066-1071, Rajput,A.H.,et al, 1997
Entacapone Improves Motor Fluctuations in Levodopa-Treated Parkinson's Dis Pts
Parkinson Study Group, Ann Neurol 42:747-7551997., , 1997
Multicenter, Placebo-Controlled Trial of Cabergoline Taken Once Daily in the Treatment of Parkinson's Disease
Neurol 46:1062-1065, Hutton,J.T.,et al, 1996
Double-Blind Comparison of Cabergoline & Bromocriptine in Parkinson's Disease Pts with Motor Fluctuations
Neurol 47:785-788, Inzelberg,R.,et al, 1996
Liquid Levodopa/Carbidopa Produces Significant Improvement in Motor Function without Dyskinesia Exacerbation
Neurol 47:1493-1495, Pappert,E.J.,et al, 1996
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Fluctuating Parkinson's Disease:Treatment with the Long-Acting Dopamine Agonist Cabergoline
Arch Neurol 51:1236-1241, Ahlskog,J.E.,et al, 1994
Multictr Study of Cabergoline, A Long-Acting Dopamine Receptor Agonist, in PD Fluct Resp to Levodopa/Carbidopa
Neurol 43:1981-1984, Lieberman,A.,et al, 1993
Protein Redistribution Diet Remains Effective in Patients with Fluctuating Parkinsonism
Arch Neurol 49:149-151, Karstaedt,P.J.&Pincus,J.H., 1992
Intranasal Apomorphine in Parkinsonian On-Off Fluctuations
Arch Neurol 49:482-484, vanLaar,T.,et al, 1992
Dopamine Agonist Treatment of Fluctuating Parkinsonisn
Arch Neurol 49:560-568, Ahlskog,J.E.,et al, 1992
Unilateral Transpl of Human Fetal Mesencephalic Tissue Into the Caudate Nucleus of Pts with Parkinson's
NEJM 327:1541-1548, Spencer,D.D.,et al, 1992
Survival of Implanted Fetal Dopamine Cells & Neuro Improvement 12 to 46 Months after Transpl for Parkinson's
NEJM 327:1549-1555, 15891992., Freed,C.R.,et al, 1992
Early Development of Levodopa-Induced Dyskinesias and Response Fluctuations in Young-Onset Parkinson's Disease
Neurol 41:202-205, Kostic,V., 1991
Intranasal Apomorphine in Parkinson's Disease
Neurol 41:761-762, Kleedorfer,B.,et al, 1991
Standard & Controlled-Release Levodopa/Carbidopa in Fluctuating Parkinson's Disease on a Protein Redistribution Diet
Arch Neurol 48:402-405, Karstaedt,P.J.,et al, 1991
Subcutaneous Apomorphine in the Treatment of Parkinson's Disease
JNNP 53:96-101, Frankel,J.P.,et al, 1990
Nasogastric and Intravenous Infusions of (+) -4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's Disease
JNNP 53:102-105, 1990, Coleman,R.J.,et al, 1990
Amount and Distribution of Dietary Protein Affects Clinical Response to Levodopa in Parkinson's Disease
Neurol 39:552-556, Carter,J.H., 1989